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Abstract The MHCII associated invariant chain isoform Ii41
shows homology to a repeat in thyroglobulin (TgR). We show
that the Ii31 isoform, which lacks the TgR-like domain, is
sensitive to cathepsin L treatment whereas Ii41 displays sub-
stantial resistance. The TgR-like sequence of Ii41 was exchanged
for thyroglobulin type-IA and -IB repeats, that contain six or
four cysteine residues. Resistance to cathepsin L digestion was
maintained upon substitution of the Ii41 TgR for homologous
sequences from TgR type-IA. Mutation of a conserved cysteine
in the TgR domain of an Ii fusion protein strongly reduced
resistance to cathepsin L digestion. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Thyroglobulin, the precursor of thyroid hormones, contains
a domain with ten repeats that include six or four cysteine
residues (TgR type-IA or -IB) [1^3]. In the MHCII associated
invariant chain (Ii41), a sequence homologous to the TgR
type-IA is encoded by an alternatively spliced exon of the Ii
gene [4]. First evidence for a functional role of this TgR-like
domain of Ii was obtained when a fragment of Ii41 was co-
isolated with cathepsin L [5]. Inhibition of enzyme catalyzed
substrate conversion revealed that the Ii41 fragment blocks
the function of cathepsin L [6]. The crystal structure of the
Ii41 TgR-like fragment shows a three loop arrangement sta-
bilized by three disul¢de bonds with the wedge shaped Ii41
fragment anchored in the active center of cathepsin L [7]. The
importance of this ¢nding is apparent [8] as the regulated
degradation of Ii governs the uptake of antigenic peptides
by MHCII dimers, a key step in initiating an immune re-
sponse. Ii is a substrate for cathepsin L under physiological
conditions, as was shown using cathepsin L de¢cient mice [9].
TgR-like domains are found in an increasing number of
functionally unrelated proteins from di¡erent species [10].
Some of the proteins contain several TgR-like domains. Ef-
forts have been made to identify the function of these do-
mains. Partial proteolysis has been used to separate TgR-
like domains in equistatin from sea anemone [11]. One of
the fragments was an inhibitor of cysteine proteases, while
another fragment blocks cathepsin D.
To determine whether TgR-like domains other than the Ii41
inhibit the function of cathepsin L, the Ii41 TgR domain was
exchanged for TgR type-IA and -IB elements from bovine
thyroglobulin or a homologous sequence from human epithe-
lial glycoprotein (EGP). We show here that Ii TgR recombi-
nant molecules exhibit a remarkable resistance to cathepsin L
digestion.
2. Materials and methods
2.1. Transfection, labeling, immunoprecipitation and SDS^PAGE
5U105 COS cells were transfected with 1 Wg plasmid DNA and
10 Wg cationic lipid (DOSPER, Boehringer-Mannheim, Germany).
Fusion of the lipid complex with cell membranes was accomplished
by addition of 10% FCS. Cells were labeled for 30 min with 30 WCi
[35S]methionine (Amersham) and lysed with 1% NP40 [12]. Ii was
immunoprecipitated by a mixture of mAb In1 (rat anti-mouse Ii),
mAb MAR18.5 (anti-rat Ig), and 10 Wl protein A Sepharose CL4B.
Following overnight incubation, precipitates were washed four times
and analyzed on SDS^polyacrylamide gels. Gels were dried and radio-
activity was visualized by exposure to X-ray ¢lms.
2.2. Cathepsin L digestion of Ii
Cathepsin L (Calbiochem) was adjusted to 0.05 WU/ml to achieve
degradation of wild-type Ii41 within 24 h. Ii immunoprecipitates im-
mobilized with protein A Sepharose were suspended in 15 Wl of 20 mU
cathepsin L/ml in 0.04 M citrate bu¡er, pH 5. The cysteine protease
was activated by 5 mM L-cysteine and Ii was digested at 37‡C. The
digestion was stopped by SDS sample bu¡er (pH 7.8) and 5 min
boiling. Protein fragments were separated by SDS^PAGE.
2.3. Mutagenesis of the Ii41 TgR domain
Sequences of the TgR-like domain of murine Ii were substituted
with TgR domain I.1 (type-IA) or I.9 (type-IB) encoded by the bovine
thyroglobulin gene [13] or the TgR domain encoded by the human
epithelial glycoprotein (EGP) gene using published methods [14].
Sequences of domain I.1 [13] were ampli¢ed using primer p41.TgI.
1/5 (5P-GTCTACCCGGGTGCGTTCCGTCCCCAGTGCGCCGA-
GGATGGC-3P) in combination with p41.TgI.1/3 (5P-GTCTTCC-
ATGTCCAGTGGCTCCAGACAGGCCGCAGGCCGCCC-3P). Se-
quences binding to Ii41 cDNA are underlined.
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Bovine TgR domain I.9 was ampli¢ed using primer p41.TgI.9/5 (5P-
GTCTACCCGGGTGCGTTCCGTCCAACCTGCTTAGAGACAG-
GA-3P) in combination with p41.TgI.9/3 (5P-GTCTTCCATGTC-
CAGTGGCTCCGGGCACTGGGCACTGCTGTT-3P). Sequences
of the TgR domain of EGP [15] were ampli¢ed using primers
p41.EGP/5 (5P-GGGTGCGTTCCGTCCTGACTGCGATGAG-3P)
and p41.EGP/3 (5P-TAGGTCTTCCATGTCCAGTGGCTCAGAG-
CAGGTTATTTCAGT-3P). The reaction mix contained 10 mM
Tris/HCl, pH 8.4, 50 mM KCl, 0.1 mg/ml gelatin, 200 WM dNTPs,
100 pM phosphorylated primers, MgCl2 (1.5 mM) for bovine TgR I.1
or EGP and TgR, 4.5 mM for bovine TgR I.9, 50 ng of plasmid
containing the target DNA and 2.5 U Taq DNA polymerase (Boehr-
inger-Mannheim). The enzyme was added after initial denaturation.
Products representing the bovine TgR I.1 and I.9 were phosphorylat-
ed using polynucleotide kinase. PCR products were mixed (50:1) with
plasmid pUC18.Ii41 containing the Ii41 cDNA. Annealing was per-
formed by heating the samples to 100‡C for 5 min and immediate
cooling on ice. Four Wl of 100 mM Tris/HCl, pH 7.5, 5 mM dNTPs,
10 mM ATP, 20 mM DTT, 2 Wl H2O, 1 Wl T4 DNA polymerase
(Amersham/USB; 3.5 U/Wl) and 3 Wl T4 DNA ligase (Amersham/
USB; 1 U/Wl) were added. The samples were incubated at 4‡C for
5 min, at room temperature (RT) for 5 min and at 37‡C for 120 min.
Aliquots were used to transform Escherichia coli strain BMH 71-18
mutS by electroporation. 200 ng of plasmids puri¢ed from overnight
bacteria cultures were digested with restriction enzyme SacII and ali-
quots were used in electro-transformation of E. coli strain DH5K.
DNA fragments encoding Ii41 with a substituted TgR-like domain
were subcloned into expression vector pcEXV3 and sequence substi-
tutions were con¢rmed by nucleotide sequencing.
3. Results
3.1. Di¡erential sensitivity of Ii31 and Ii41 to
cathepsin L digestion
To investigate degradation of the two Ii isoforms by cathep-
sin L in vitro, we expressed Ii31 or Ii41 cDNA in COS cells.
After metabolic labeling with [35S]methionine, cells were lysed
and Ii was immunoprecipitated with mAb In1 and subse-
quently digested with cathepsin L. Ii31 is rapidly degraded
to fragments in the range of 25 kDa and 10^12 kDa (Fig.
1A). In contrast, Ii41 exhibits a substantial resistance to deg-
radation by cathepsin L (Fig. 1B) with complete digest taking
longer than 16 h. Since the TgR domain of Ii41 responsible
for inhibition of cathepsin L [6] was also found in other pro-
teins, we wanted to determine whether homologous TgR do-
mains exhibit an inhibitory function on Ii degradation by ca-
thepsin L. Recombinant Ii chains were constructed where aa
213^255 of the Ii41 sequence were replaced by homologous
sequences of TgR (type-IA or -IB repeats) or of EGP (Fig. 2).
In addition, a mutant Ii chain, Ii EGPC/F was generated. The
mutant shows an exchange of Cys-215 for Phe of the EGP-
TgR domain, which disrupts the disul¢de bond in the ¢rst
loop.
3.2. Structural requirements of the TgR for inhibition of
cathepsin L
To test for inhibition of cathepsin L digestion, recombinant
Ii chains were immunoprecipitated from transfected COS cells
and digested (Fig. 3). Proteolysis of Ii TgR I.1 (Fig. 3A) and
Fig. 1. Digestion of Ii31 and of Ii41 with cathepsin L. COS cells were transiently transfected with cDNA encoding Ii31 (A) or Ii41 (B). Cells
were labeled with [35S]methionine and Ii was immunoprecipitated with mAb In1. Immobilized Ii immunoprecipitates were digested with
20 mU/ml of cathepsin L. The digestion was stopped after 0.5, 1, 2, 4, 8, and 16 h by SDS sample bu¡er and boiling. Ii and its degradation
products are separated by SDS^PAGE. Mobilities of proteins are indicated at the right and molecular weight markers on the left.
Fig. 2. Partial sequence of the Ii41 domain and Ii TgR fusion proteins. The sequence aa 213^255 of Ii41 was exchanged for sequences from bo-
vine thyroglobulin type-IA or -IB repeats (TgR I.1 or TgR I.9), by EGP, or by the mutant EGPC/F. The type-IA TgR repeat consists of three
loops that are stabilized by disul¢de bonds. To minimize structural changes to the Ii fusion protein, the sequence of the ¢rst loop that shows
most variable length in the TgR domains was not exchanged. In TgR I.9 (type-IB repeat) which contains only four cysteines, the second disul-
¢de bond cannot form. EGPC/F has Cys-215 exchanged by Phe. Locations of disul¢de bonds are indicated. Regions with a high degree of con-
servation are boxed. The Ii41 sequence is shaded.
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of Ii EGP (Fig. 3B) revealed that both polypeptides exhibit a
reduced, but still substantial resistance to cathepsin L treat-
ment when compared to wild-type Ii41 (Fig. 1A). The TgR
type-IB variant expressed in Ii TgR I.9 (Fig. 3C) shows rapid
proteolysis by cathepsin L treatment that resembles the rate of
digestion of Ii31 (Fig. 1B), suggesting that the absence of the
disul¢de bond in the second loop of the TgR type-IB repeat
results in a reduced sensitivity to the protease. Similarly, ex-
change of Cys-215 in Ii EGPC/F (Fig. 2) that prevents the
¢rst disul¢de bond largely abolishes the resistance to cathep-
sin L digestion (Fig. 3D). This recombinant Ii chain is almost
as sensitive to degradation by cathepsin L as wild-type Ii31
(Figs. 1B and 3D).
For a semiquantitative comparison the decay constants of
recombinant Ii chain degradation by cathepsin L were deter-
mined. The chimeric TgR I.1 and EGP show decay constants
of k = 1U1034 s31 and k = 2U1034 s31 compared to a k of
about 5U1035 s31 for Ii41. This result may suggest that in-
hibitory constants of TgR I.1 and EGP for cathepsin L activ-
ity are markedly lower than that of Ii41.
4. Discussion
Ii is expressed in two forms, Ii31 and Ii41, that di¡er in a 64
aa sequence containing a TgR-like domain [4]. An immuno-
logical function of the TgR-like domain in Ii41 has not yet
been elucidated. Antigen presenting cells that express either
Ii31 or Ii41 process and present antigen equally [16]. This
result was con¢rmed in recombinant mice, expressing either
Ii31 or Ii41, which show a similar phenotype [17]. The role of
the TgR-like domain in Ii41 could be to modulate degradation
of antigenic peptides or to provide a mechanism to regulate
degradation of Ii by cathepsin L. The di¡erent susceptibility
of Ii31 and Ii41 to degradation by cathepsin L, as shown in
this report (Fig. 1), points to a mechanism of modulating the
release of Ii from MHCII molecules. This ¢nding might pro-
vide an explanation why Ii41 has a prolonged half life com-
pared to Ii31 [18].
Both Ii31 and Ii41 form trimers and are present in the same
complex [19]. Although in most cells Ii31 is expressed more
abundantly than Ii41, in some cell types, like DC, macro-
phages and Langerhans cells, the amount of Ii41 approaches
30^40% of total Ii expression [18]. Using transfected cells, it
was shown that the presence of Ii41 in Ii trimers hampers
degradation of Ii31 [20]. Upon release of Ii, MHCII dimers
become susceptible for binding of antigenic peptides [21].
Hence the inhibition of cathepsin L by Ii41 may delay loading
of MHCII dimers with peptides.
The main characteristics of the TgR domain are a Cys-Trp-
Cys-Val motif and two or four additional cysteines that sta-
bilize the structure by two to three disul¢de bonds. Although
the aa residues that maintain the tertiary structure of the TgR
domain, as revealed by the crystal structure [7], are highly
conserved among divers proteins, the total identity of the
sequences is less than 26%. Thus, it is remarkable that ex-
change of the TgR-like domain of Ii41 by homologous se-
quences from bovine TgR and human EGP, still resulted in
retention of the domain’s inhibitory function (Fig. 3).
It is as yet unknown whether the type-IA TgR repeat exerts
a cathepsin L inhibitory function in situ. Cathepsin L has
Fig. 3. Digestion of recombinant Ii by cathepsin L. Ii TgR I.1 (A), Ii EGP (B), Ii TgR I.9 (C), and Ii EGPC/F (D) were transiently expressed
in COS cells, labeled with [35S]methionine and immunoprecipitated with mAb In1. Immunoprecipitates were digested with 20 mU/ml cathepsin
L. Digestion was stopped by addition of SDS sample bu¡er. Samples were separated by SDS^PAGE. Molecular weight markers are shown on
the left.
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been detected on the lumenal plasma membrane of thyrocytes
[22]. TgR might, therefore, be able to regulate cathepsin L
activity in the follicular lumen and to inhibit precocious pro-
teolysis of thyroglobulin.
The discovery of the TgR-like domain in a number of pro-
teins suggests widespread importance. TgR homologous se-
quences have also been found in a cysteine proteinase inhib-
itor from Actinia equina [23] and a sequence from
Caenorabditis elegans [24] (gb/AAB92030.2/). The presence
of the TgR-like domain in invertebrates suggests that a pro-
tease inhibitory function predates the immune system. Possi-
bly, the protease inhibitory function of the TgR-like domain
of Ii41 embodies an early evolutionary defense mechanism,
e.g. to parasites such as Leishmania or Trypanosoma cruzi.
These organisms require cysteine proteases for survival and
invasion [25].
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